| HOME >> BIOLOGY >> TECHNOLOGY |
recognition of a deferred credit and the decrease in goodwill and
deferred income taxes liabilities based on the final purchase price
allocation in connection with FISH acquisition upon completion of
independent valuation.
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
For the Three Months Ended
June 30,
September 2007 September 30,
30, 2006 Restated(2) 2007
RMB RMB RMB US$
(in thousands except for per ADS
information)
Revenues, net (1) 131,411 151,490 214,896 28,680
Cost of revenues (36,973) (64,364) (82,687) (11,036)
Gross profit 94,438 87,126 132,209 17,644
Operating expenses:
Research and development (8,377) (9,779) (8,096) (1,081)
Sales and marketing (4,457) (5,755) (6,618) (883)
General and administrative (12,026) (13,946) (20,929) (2,793)
Total operating expenses (24,860) (29,480) (35,643) (4,757)
Operating income 69,578 57,646 96,566 12,887
Other income 1,100 100 -- --
Interest income 7,970 8,694 7,785 1,039
Interest expense -
convertible notes -- (10,078) (9,920) (1,324)
Interest expense - other -- (1,569) (1,180) (157)
Amortization of convertible
notes issuance cost
'/>"/>
| SOURCE China Medical Technologies, Inc. Copyright©2007 PR Newswire. All rights reserved |